215 related articles for article (PubMed ID: 33512796)
1. Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease.
Croese J; Miller GC; Marquart L; Llewellyn S; Gupta R; Becker L; Clouston AD; Welch C; Sidorenko J; Wallace L; Visscher PM; Remedios ML; McCarthy JS; O'Rourke P; Radford-Smith G; Loukas A; Norrie M; Masson JW; Gearry RB; Rahman T; Giacomin PR
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00274. PubMed ID: 33512796
[TBL] [Abstract][Full Text] [Related]
2. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease.
Croese J; Giacomin P; Navarro S; Clouston A; McCann L; Dougall A; Ferreira I; Susianto A; O'Rourke P; Howlett M; McCarthy J; Engwerda C; Jones D; Loukas A
J Allergy Clin Immunol; 2015 Feb; 135(2):508-16. PubMed ID: 25248819
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial.
Chapman PR; Webster R; Giacomin P; Llewellyn S; Becker L; Pearson MS; De Labastida Rivera F; O'Rourke P; Engwerda CR; Loukas A; McCarthy JS
Lancet Infect Dis; 2021 Dec; 21(12):1725-1736. PubMed ID: 34419209
[TBL] [Abstract][Full Text] [Related]
4. Changed gluten immunity in celiac disease by Necator americanus provides new insights into autoimmunity.
Croese J; Gaze ST; Loukas A
Int J Parasitol; 2013 Mar; 43(3-4):275-82. PubMed ID: 23291460
[TBL] [Abstract][Full Text] [Related]
5. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study.
Tack GJ; van de Water JM; Bruins MJ; Kooy-Winkelaar EM; van Bergen J; Bonnet P; Vreugdenhil AC; Korponay-Szabo I; Edens L; von Blomberg BM; Schreurs MW; Mulder CJ; Koning F
World J Gastroenterol; 2013 Sep; 19(35):5837-47. PubMed ID: 24124328
[TBL] [Abstract][Full Text] [Related]
6. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
[TBL] [Abstract][Full Text] [Related]
7. Effect of hookworm infection on wheat challenge in celiac disease--a randomised double-blinded placebo controlled trial.
Daveson AJ; Jones DM; Gaze S; McSorley H; Clouston A; Pascoe A; Cooke S; Speare R; Macdonald GA; Anderson R; McCarthy JS; Loukas A; Croese J
PLoS One; 2011 Mar; 6(3):e17366. PubMed ID: 21408161
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of experimental hookworm infection in humans with metabolic disease: study protocol for a phase 1b randomised controlled clinical trial.
Pierce D; Merone L; Lewis C; Rahman T; Croese J; Loukas A; McDonald M; Giacomin P; McDermott R
BMC Endocr Disord; 2019 Dec; 19(1):136. PubMed ID: 31829172
[TBL] [Abstract][Full Text] [Related]
10. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease.
Catassi C; Fabiani E; Iacono G; D'Agate C; Francavilla R; Biagi F; Volta U; Accomando S; Picarelli A; De Vitis I; Pianelli G; Gesuita R; Carle F; Mandolesi A; Bearzi I; Fasano A
Am J Clin Nutr; 2007 Jan; 85(1):160-6. PubMed ID: 17209192
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial.
Hoogerwerf MA; Janse JJ; Kuiper VP; van Schuijlenburg R; Kruize YC; Sijtsma JC; Nosoh BA; Koopman JR; Verbeek-Menken PH; Westra IM; Meij P; Brienen EA; Visser LG; van Lieshout L; Jochems SP; Yazdanbakhsh M; Roestenberg M
Lancet Microbe; 2023 Dec; 4(12):e1024-e1034. PubMed ID: 38042152
[TBL] [Abstract][Full Text] [Related]
12. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
Lähdeaho ML; Kaukinen K; Laurila K; Vuotikka P; Koivurova OP; Kärjä-Lahdensuu T; Marcantonio A; Adelman DC; Mäki M
Gastroenterology; 2014 Jun; 146(7):1649-58. PubMed ID: 24583059
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D; Mäki M; Lundin KEA; Isola J; Friesing-Sosnik T; Taavela J; Popp A; Koskenpato J; Langhorst J; Hovde Ø; Lähdeaho ML; Fusco S; Schumann M; Török HP; Kupcinskas J; Zopf Y; Lohse AW; Scheinin M; Kull K; Biedermann L; Byrnes V; Stallmach A; Jahnsen J; Zeitz J; Mohrbacher R; Greinwald R;
N Engl J Med; 2021 Jul; 385(1):35-45. PubMed ID: 34192430
[TBL] [Abstract][Full Text] [Related]
14. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.
Skodje GI; Sarna VK; Minelle IH; Rolfsen KL; Muir JG; Gibson PR; Veierød MB; Henriksen C; Lundin KEA
Gastroenterology; 2018 Feb; 154(3):529-539.e2. PubMed ID: 29102613
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
Leffler DA; Kelly CP; Abdallah HZ; Colatrella AM; Harris LA; Leon F; Arterburn LA; Paterson BM; Lan ZH; Murray JA
Am J Gastroenterol; 2012 Oct; 107(10):1554-62. PubMed ID: 22825365
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.
Leonard MM; Silvester JA; Leffler D; Fasano A; Kelly CP; Lewis SK; Goldsmith JD; Greenblatt E; Kwok WW; McAuliffe WJ; Galinsky K; Siegelman J; Chow IT; Wagner JA; Sapone A; Smithson G
Gastroenterology; 2021 Feb; 160(3):720-733.e8. PubMed ID: 33130104
[TBL] [Abstract][Full Text] [Related]
17. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection.
McSorley HJ; Gaze S; Daveson J; Jones D; Anderson RP; Clouston A; Ruyssers NE; Speare R; McCarthy JS; Engwerda CR; Croese J; Loukas A
PLoS One; 2011; 6(9):e24092. PubMed ID: 21949691
[TBL] [Abstract][Full Text] [Related]
18. Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.
Tanasescu R; Tench CR; Constantinescu CS; Telford G; Singh S; Frakich N; Onion D; Auer DP; Gran B; Evangelou N; Falah Y; Ranshaw C; Cantacessi C; Jenkins TP; Pritchard DI
JAMA Neurol; 2020 Sep; 77(9):1089-1098. PubMed ID: 32539079
[TBL] [Abstract][Full Text] [Related]
19. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial.
Biesiekierski JR; Newnham ED; Irving PM; Barrett JS; Haines M; Doecke JD; Shepherd SJ; Muir JG; Gibson PR
Am J Gastroenterol; 2011 Mar; 106(3):508-14; quiz 515. PubMed ID: 21224837
[TBL] [Abstract][Full Text] [Related]
20. Experimental hookworm infection and escalating gluten challenges are associated with increased microbial richness in celiac subjects.
Giacomin P; Zakrzewski M; Croese J; Su X; Sotillo J; McCann L; Navarro S; Mitreva M; Krause L; Loukas A; Cantacessi C
Sci Rep; 2015 Sep; 5():13797. PubMed ID: 26381211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
